Discovery of new MD2-targeted anti-inflammatory compounds for the treatment of sepsis and acute lung injury
- 1 October 2017
- journal article
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 139, 726-740
Abstract
No abstract availableKeywords
Funding Information
- National Natural Science funding of China (81622043, 81503123, 21572166)
- zhejiang province natural science funding (LY17B020008, LR16H310001)
This publication has 34 references indexed in Scilit:
- The Role of Endothelin-1 and Endothelin Receptor Antagonists in Inflammatory Response and SepsisArchivum Immunologiae et Therapiae Experimentalis, 2014
- Mortality Related to Severe Sepsis and Septic Shock Among Critically Ill Patients in Australia and New Zealand, 2000-2012JAMA, 2014
- Toll-like Receptor 4 (TLR4) Modulation by Synthetic and Natural Compounds: An UpdateJournal of Medicinal Chemistry, 2013
- Proteases and Delayed Wound HealingAdvances in Wound Care, 2013
- Neutrophil recruitment and function in health and inflammationNature Reviews Immunology, 2013
- Inflammasome-regulated Cytokines Are Critical Mediators of Acute Lung InjuryAmerican Journal of Respiratory and Critical Care Medicine, 2012
- Targeting Inflammatory Pathways for Prevention and Therapy of Cancer: Short-Term Friend, Long-Term FoeClinical Cancer Research, 2009
- Anti-Immunology: Evasion of the Host Immune System by Bacterial and Viral PathogensCell, 2006
- Ethyl pyruvate prevents lethality in mice with established lethal sepsis and systemic inflammationProceedings of the National Academy of Sciences, 2002
- The Acute Respiratory Distress SyndromeNew England Journal of Medicine, 2000